ELITE TEST
BANK:
2026/2027
PHARMACOLO
GY FOR
ANESTHESIOLO
GY MASTERY
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–15)
○ Section 2: Professional Simulation (Questions 16–40)
○ Section 3: Grandmaster Synthesis (Questions 41–66)
,PART I: THE PRIMER
Welcome to the top 1% of clinical practice. Mastering the precise pharmacology of
anesthesiology within the UT Austin APRN DNP framework does not merely pass board exams;
it averts catastrophic failure when seconds dictate human survival. You are not here to
memorize; you are here to architect hemodynamic stability and execute 2026 guidelines
flawlessly.
The 2026/2027 "Panic Button" Cheat Sheet:
● GLP-1 RAs: Assume a full stomach. Delayed gastric emptying mandates POCUS or
immediate Rapid Sequence Induction (RSI).
● Quantitative Monitoring: Train-of-Four (TOF) ratio must be ≥0.9 at the adductor pollicis
before extubation. Subjective monitoring is obsolete.
● Sugammadex: 2026 pediatric approval for children <2 years (2 mg/kg moderate, 4 mg/kg
deep block).
● Suzetrigine: 2025/2026 FDA-approved NaV1.8 inhibitor. Zero addiction potential; watch
for CYP3A interactions.
● TJC NPG 12: Staffing is a clinical safety metric. Cognitive overload directly correlates to
medication administration errors.
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application (Questions 1–15)
Q1: According to the 2026 ASA consensus guidelines, a patient taking a daily GLP-1 receptor
agonist for weight loss presents for elective surgery. What is the REQUIRED PREOPERATIVE
action regarding this medication? A) Continue the medication to avert perioperative
hyperglycemia. B) Hold the daily dose on the day of the procedure. C) Hold the medication for
exactly 14 days prior to surgery. D) Transition the patient to an insulin drip.
● The Answer: B (Hold the daily dose on the day of the procedure.)
● Distractor Analysis:
○ A is incorrect: Continuing daily dosing increases the risk of delayed gastric
emptying and aspiration.
○ C is incorrect: Only weekly doses are held 7 days prior; 14 days is unnecessary.
○ D is incorrect: Transitioning to an insulin drip is an overreaction for a patient taking
a GLP-1 solely for weight loss.
The Mentor's Analysis: The 2026 standard is explicitly clear: Hold daily GLP-1s on the day of
surgery, and weekly GLP-1s a full week prior. Professional Intuition: Never trust the stomach
of a patient on a GLP-1. Fasting times are irrelevant when pharmacology inherently paralyzes
the gut. You must assume a full stomach profile.
Q2: Under the 2026 pediatric neuromuscular blockade guidelines, which agent and dosage is
RECOMMENDED for the rapid reversal of deep rocuronium blockade in a 14-month-old infant?
A) Neostigmine 0.05 mg/kg. B) Sugammadex 2 mg/kg. C) Sugammadex 4 mg/kg. D)
Sugammadex 16 mg/kg.
● The Answer: C (Sugammadex 4 mg/kg.)
● Distractor Analysis:
○ A is incorrect: Neostigmine is inferior for deep blockade reversal and carries a high
, anticholinergic and bradycardic burden.
○ B is incorrect: 2 mg/kg is the evidence-based dose for moderate, not deep,
blockade.
○ D is incorrect: 16 mg/kg is the "rescue" dose for a Can't Intubate, Can't Ventilate
(CICV) scenario, not standard deep reversal.
The Mentor's Analysis: The 2026 data formally confirms sugammadex is safe and vastly
superior to neostigmine for neonates and infants <2 years. Professional Intuition: Deep block
explicitly requires 4 mg/kg. Do not under-dose pediatric patients out of legacy fear; encapsulate
the steroidal relaxant completely.
Q3: You are administering Suzetrigine (Journavx) as part of a 2026 ERAS protocol. Which
mechanism of action BEST describes this novel analgesic? A) Selective mu-opioid receptor
agonism. B) Non-selective cyclooxygenase (COX) inhibition. C) Selective inhibition of the
NaV1.8 voltage-gated sodium channel in the peripheral nervous system. D) NMDA receptor
antagonism.
● The Answer: C (Selective inhibition of the NaV1.8 voltage-gated sodium channel in the
peripheral nervous system.)
● Distractor Analysis:
○ A is incorrect: Suzetrigine is distinctly a non-opioid analgesic, avoiding central
mu-receptors entirely.
○ B is incorrect: This describes NSAIDs (e.g., ketorolac), which pose bleeding and
renal risks.
○ D is incorrect: This describes ketamine, which works centrally.
The Mentor's Analysis: Suzetrigine revolutionized acute pain management by specifically
targeting NaV1.8 in peripheral nociceptive C-fibers, halting pain signals before they ever reach
the brain. Professional Intuition: It blocks the wire, not the brain. You achieve profound
analgesia without sedation, respiratory depression, or the systemic toxicity of IV lidocaine.
Q4: A 65-year-old ASA III patient requires induction for a brief procedure. You select
remimazolam. What is the MOST APPROPRIATE induction dose according to 2026 labeling?
A) 5 mg IV push over 1 minute. B) 2.5 to 5 mg IV push over 1 minute. C) 1.25 mg IV push over
15 seconds. D) 10 mg IV push over 1 minute.
● The Answer: B (2.5 to 5 mg IV push over 1 minute.)
● Distractor Analysis:
○ A is incorrect: 5 mg is the standard dose for healthy adults, but ASA III/IV requires
downward titration and careful observation.
○ C is incorrect: This is the maintenance supplemental dose, not the primary
induction dose.
○ D is incorrect: 10 mg is a massive overdose that entirely defeats the drug's precise
titratability and hemodynamic profile.
The Mentor's Analysis: Remimazolam combines midazolam's familiarity with remifentanil's
ultra-short offset via tissue esterase metabolism. In sick patients (ASA III/IV), go slow and low.
Professional Intuition: Hemodynamic stability is paramount. Titrate the 2.5 mg dose and watch
the brain's response, not just the clock.
Q5: To comply with 2026 ASA Practice Guidelines, which anatomical site is MANDATORY for
quantitative neuromuscular monitoring prior to extubation? A) Orbicularis oculi. B) Corrugator
supercilii. C) Adductor pollicis. D) Flexor hallucis brevis.
● The Answer: C (Adductor pollicis.)
● Distractor Analysis:
○ A and B are incorrect: The facial muscles recover faster than the airway
BANK:
2026/2027
PHARMACOLO
GY FOR
ANESTHESIOLO
GY MASTERY
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–15)
○ Section 2: Professional Simulation (Questions 16–40)
○ Section 3: Grandmaster Synthesis (Questions 41–66)
,PART I: THE PRIMER
Welcome to the top 1% of clinical practice. Mastering the precise pharmacology of
anesthesiology within the UT Austin APRN DNP framework does not merely pass board exams;
it averts catastrophic failure when seconds dictate human survival. You are not here to
memorize; you are here to architect hemodynamic stability and execute 2026 guidelines
flawlessly.
The 2026/2027 "Panic Button" Cheat Sheet:
● GLP-1 RAs: Assume a full stomach. Delayed gastric emptying mandates POCUS or
immediate Rapid Sequence Induction (RSI).
● Quantitative Monitoring: Train-of-Four (TOF) ratio must be ≥0.9 at the adductor pollicis
before extubation. Subjective monitoring is obsolete.
● Sugammadex: 2026 pediatric approval for children <2 years (2 mg/kg moderate, 4 mg/kg
deep block).
● Suzetrigine: 2025/2026 FDA-approved NaV1.8 inhibitor. Zero addiction potential; watch
for CYP3A interactions.
● TJC NPG 12: Staffing is a clinical safety metric. Cognitive overload directly correlates to
medication administration errors.
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application (Questions 1–15)
Q1: According to the 2026 ASA consensus guidelines, a patient taking a daily GLP-1 receptor
agonist for weight loss presents for elective surgery. What is the REQUIRED PREOPERATIVE
action regarding this medication? A) Continue the medication to avert perioperative
hyperglycemia. B) Hold the daily dose on the day of the procedure. C) Hold the medication for
exactly 14 days prior to surgery. D) Transition the patient to an insulin drip.
● The Answer: B (Hold the daily dose on the day of the procedure.)
● Distractor Analysis:
○ A is incorrect: Continuing daily dosing increases the risk of delayed gastric
emptying and aspiration.
○ C is incorrect: Only weekly doses are held 7 days prior; 14 days is unnecessary.
○ D is incorrect: Transitioning to an insulin drip is an overreaction for a patient taking
a GLP-1 solely for weight loss.
The Mentor's Analysis: The 2026 standard is explicitly clear: Hold daily GLP-1s on the day of
surgery, and weekly GLP-1s a full week prior. Professional Intuition: Never trust the stomach
of a patient on a GLP-1. Fasting times are irrelevant when pharmacology inherently paralyzes
the gut. You must assume a full stomach profile.
Q2: Under the 2026 pediatric neuromuscular blockade guidelines, which agent and dosage is
RECOMMENDED for the rapid reversal of deep rocuronium blockade in a 14-month-old infant?
A) Neostigmine 0.05 mg/kg. B) Sugammadex 2 mg/kg. C) Sugammadex 4 mg/kg. D)
Sugammadex 16 mg/kg.
● The Answer: C (Sugammadex 4 mg/kg.)
● Distractor Analysis:
○ A is incorrect: Neostigmine is inferior for deep blockade reversal and carries a high
, anticholinergic and bradycardic burden.
○ B is incorrect: 2 mg/kg is the evidence-based dose for moderate, not deep,
blockade.
○ D is incorrect: 16 mg/kg is the "rescue" dose for a Can't Intubate, Can't Ventilate
(CICV) scenario, not standard deep reversal.
The Mentor's Analysis: The 2026 data formally confirms sugammadex is safe and vastly
superior to neostigmine for neonates and infants <2 years. Professional Intuition: Deep block
explicitly requires 4 mg/kg. Do not under-dose pediatric patients out of legacy fear; encapsulate
the steroidal relaxant completely.
Q3: You are administering Suzetrigine (Journavx) as part of a 2026 ERAS protocol. Which
mechanism of action BEST describes this novel analgesic? A) Selective mu-opioid receptor
agonism. B) Non-selective cyclooxygenase (COX) inhibition. C) Selective inhibition of the
NaV1.8 voltage-gated sodium channel in the peripheral nervous system. D) NMDA receptor
antagonism.
● The Answer: C (Selective inhibition of the NaV1.8 voltage-gated sodium channel in the
peripheral nervous system.)
● Distractor Analysis:
○ A is incorrect: Suzetrigine is distinctly a non-opioid analgesic, avoiding central
mu-receptors entirely.
○ B is incorrect: This describes NSAIDs (e.g., ketorolac), which pose bleeding and
renal risks.
○ D is incorrect: This describes ketamine, which works centrally.
The Mentor's Analysis: Suzetrigine revolutionized acute pain management by specifically
targeting NaV1.8 in peripheral nociceptive C-fibers, halting pain signals before they ever reach
the brain. Professional Intuition: It blocks the wire, not the brain. You achieve profound
analgesia without sedation, respiratory depression, or the systemic toxicity of IV lidocaine.
Q4: A 65-year-old ASA III patient requires induction for a brief procedure. You select
remimazolam. What is the MOST APPROPRIATE induction dose according to 2026 labeling?
A) 5 mg IV push over 1 minute. B) 2.5 to 5 mg IV push over 1 minute. C) 1.25 mg IV push over
15 seconds. D) 10 mg IV push over 1 minute.
● The Answer: B (2.5 to 5 mg IV push over 1 minute.)
● Distractor Analysis:
○ A is incorrect: 5 mg is the standard dose for healthy adults, but ASA III/IV requires
downward titration and careful observation.
○ C is incorrect: This is the maintenance supplemental dose, not the primary
induction dose.
○ D is incorrect: 10 mg is a massive overdose that entirely defeats the drug's precise
titratability and hemodynamic profile.
The Mentor's Analysis: Remimazolam combines midazolam's familiarity with remifentanil's
ultra-short offset via tissue esterase metabolism. In sick patients (ASA III/IV), go slow and low.
Professional Intuition: Hemodynamic stability is paramount. Titrate the 2.5 mg dose and watch
the brain's response, not just the clock.
Q5: To comply with 2026 ASA Practice Guidelines, which anatomical site is MANDATORY for
quantitative neuromuscular monitoring prior to extubation? A) Orbicularis oculi. B) Corrugator
supercilii. C) Adductor pollicis. D) Flexor hallucis brevis.
● The Answer: C (Adductor pollicis.)
● Distractor Analysis:
○ A and B are incorrect: The facial muscles recover faster than the airway
